» Articles » PMID: 11016658

Increased Expression of Insulin-like Growth Factor I Receptor in Malignant Cells Expressing Aberrant P53: Functional Impact

Overview
Journal Cancer Res
Specialty Oncology
Date 2000 Oct 4
PMID 11016658
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the functional impact of p53 on insulin-like growth factor I receptor (IGF-IR) expression in malignant cells. Using the BL-41tsp53-2 cell line, a transfectant carrying temperature-sensitive (ts) p53 and endogenous mutant p53 (codon 248), we demonstrated a drastic down-regulation of plasma membrane-bound IGF-IRs on induction of wild-type p53. However, a similar response was obtained by treatment of BL-41tsp53-2 cells expressing mutant ts p53 with a p53 antisense oligonucleotide. Thus, even if the negative effect of wild-type p53 predominates under a competitive condition, these data indicate that mutant p53 may be important for up-regulation of IGF-IR. To further elucidate this issue, three melanoma cell lines (BE, SK-MEL-5, and SK-MEL-28) that overexpressed p53 were investigated. The BE cell line has a "hot spot" mutation (codon 248) and expresses only codon 248-mutant p53. SK-MEL-28 has a point mutation at codon 145. SK-MEL-5 cells did not exhibit any p53 mutations, but the absence of p21Waf1 expression suggested functionally aberrant p53. Our data suggest that interaction with Mdm-2 may underlie p53 inactivation in these cells. Using p53 antisense oligonucleotides, we demonstrated a substantial down-regulation of cell surface expression of IGF-IR proteins in all melanoma cell lines after 24 h. This was paralleled by decreased tyrosine phosphorylation of IGF-IR and growth arrest, and, subsequently, massive cell death was observed (this was also seen in BL-41tsp53-2 cells with mutant conformation of ts p53). Taken together, our results suggest that up-regulation of IGF-IR as a result of expression of aberrant p53 may be important for the growth and survival of malignant cells.

Citing Articles

The IGF1 Signaling Pathway: From Basic Concepts to Therapeutic Opportunities.

Werner H Int J Mol Sci. 2023; 24(19).

PMID: 37834331 PMC: 10573540. DOI: 10.3390/ijms241914882.


Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?.

Haronikova L, Bonczek O, Zatloukalova P, Kokas-Zavadil F, Kucerikova M, Coates P Cell Mol Biol Lett. 2021; 26(1):53.

PMID: 34911439 PMC: 8903693. DOI: 10.1186/s11658-021-00293-6.


IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma.

Song D, Cismas S, Crudden C, Trocme E, Worrall C, Suleymanova N Oncogene. 2021; 41(4):600-611.

PMID: 34785779 DOI: 10.1038/s41388-021-02111-x.


Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients.

Oliveres H, Pesantez D, Maurel J Int J Mol Sci. 2021; 22(9).

PMID: 34065119 PMC: 8126031. DOI: 10.3390/ijms22095019.


Laron Syndrome Research Paves the Way for New Insights in Oncological Investigation.

Werner H, Sarfstein R, Nagaraj K, Laron Z Cells. 2020; 9(11).

PMID: 33182502 PMC: 7696416. DOI: 10.3390/cells9112446.